Larimar Therapeutics (LRMR) Net Equity Issued and Repurchased (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Net Equity Issued and Repurchased for 8 consecutive years, with -$201000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$201000.0; the trailing twelve-month figure through Dec 2025 stood at -$546000.0 (down 100.34% YoY), and the FY2025 full-year result was $65.1 million, down 59.78% from the prior year.
• Net Equity Issued and Repurchased grew to -$201000.0 in Q4 2025 per LRMR's latest filing, from -$345000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $162.2 million in Q1 2024 and bottomed at -$345000.0 in Q2 2024.
• Historically, Net Equity Issued and Repurchased has averaged $36.2 million across 4 years, with a median of -$201000.0 in 2025.
• The widest YoY moves for Net Equity Issued and Repurchased: up 14681.48% in 2021, down 14681.48% in 2021.
• Over 4 years, Net Equity Issued and Repurchased stood at $19.7 million in 2021, then plunged by 101.61% to -$316000.0 in 2022, then decreased by 9.18% to -$345000.0 in 2024, then soared by 41.74% to -$201000.0 in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$201000.0, -$345000.0, and $162.2 million for Q4 2025, Q2 2024, and Q1 2024 respectively.